SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Capital Royalty L.P. (Last) (First) (Middle) 1000 MAIN ST., SUITE 2500 (Street) HOUSTON TX 77002 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/31/2019	3. Issuer Name and Ticker or Trading Symbol Egalet Corp [ EGLT ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,586,874	I	By Iroko Properties Inc.(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(2)	(2)	Common Stock	2,436,459	$0.001	I	By Iroko Properties Inc.(1)

1. Name and Address of Reporting Person* Capital Royalty L.P. (Last) (First) (Middle) 1000 MAIN ST., SUITE 2500 (Street) HOUSTON TX 77002 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* CRG Partners III - Parallel Fund B (Cayman) L.P. (Last) (First) (Middle) 1000 MAIN ST., SUITE 2500 (Street) HOUSTON 77002 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* CRG Partners III - Parallel Fund (A) L.P. (Last) (First) (Middle) 1000 MAIN ST., SUITE 2500 (Street) HOUSTON 77002 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Iroko Pharmaceuticals Inc. (Last) (First) (Middle) 150 ROUSE BOULEVARD (Street) PHILADELPHIA PA 19112 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Iroko Properties Inc. (Last) (First) (Middle) 150 ROUSE BOULEVARD (Street) PHILADELPHIA PA 19112 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* CRG Partners III (Cayman) Lev AIV I L.P. (Last) (First) (Middle) 1000 MAIN ST., SUITE 2500 (Street) HOUSTON TX 77002 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* CRG Partners III (Cayman) Unlev AIV I L.P. (Last) (First) (Middle) 1000 MAIN ST., SUITE 2500 (Street) HOUSTON TX 77002 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* CRG Partners III L.P. (Last) (First) (Middle) 1000 MAIN ST., SUITE 2500 (Street) HOUSTON TX 77002 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. The shares of Common Stock (the "Shares") and the Warrants are owned directly by Iroko Properties Inc., which is a wholly owned subsidiary of Iroko Pharmaceuticals Inc. CRG Partners III - Parallel Fund "B" (Cayman) L.P., CRG Partners III (Cayman) Lev AIV I L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III L.P. and CRG Partners III - Parallel Fund "A" L.P. (collectively, the "Funds") collectively hold all of the issued and outstanding shares of Iroko Pharmaceuticals Inc. CR Group L.P. may be deemed to beneficially own the Shares and the Warrants by virtue of its position as the investment manager for the Funds. This Form 3 is filed jointly by Iroko Pharmaceuticals Inc., Iroko Properties Inc., CR Group L.P. and each of the Funds.

2. Pursuant to the terms of the Warrants, Iroko Properties Inc. has the right to acquire up to 2,436,459 additional shares of Common Stock, provided however that, for a period of eighteen (18) months following the date of the issuance of the Warrants, Iroko Properties Inc.'s right to exercise the Warrants is restricted so that it does not hold more than 49% of the issued and outstanding shares of Common Stock of the Issuer. The Warrants do not have an expiration date.

Remarks:

	/s/Nathan D. Hukill, authorized signatory for CR Group L.P. and each of the Funds	02/11/2019
	/s/ Todd Holmes, authorized signatory for each of Iroko Pharmaceuticals Inc. and Iroko Properties Inc.	02/11/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.